NMD Pharma A/S | LinkedIn
NMD Pharma Raises €35 Million in a new Financing — NMD Pharma
NMD Pharma begins first clinical trial: "Our entire team can be enormously proud" — MedWatch
Thomas Holm Pedersen on LinkedIn: Happy to share that NMD was awarded the Startup of the Year 2022 at Aarhus…
NMD Pharma Raises €35 Million in a new Financing
Thomas Holm Pedersen – CEO – NMD Pharma A/S | LinkedIn
Jeito Capital Becomes Key Investor in NMD Pharma as Part of a €35 Million New Financing | Business Wire
NMD Pharma Raises $39.7 Million to Advance Pipeline Targeting Rare Neuromuscular Disorders - Global Genes
NMD Pharma - PIR International
Thomas Pedersen email address & phone number | NMD Pharma A/S CEO contact information - RocketReach
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
NMD Pharma Raises €35M Financing - FinSMEs
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
NMD Pharma Nears Validation For ClC-1 Inhibition With Lead Program In Myasthenia Gravis :: Scrip
Following a compound from start to finish - Nordic Life Science – the leading Nordic life science news service
Novo Seeds portfolio company NMD Pharma reports positive top-line Phase I/IIa data in myasthenia gravis - Startup Weekly
NMD Pharma (@NMDPharma) / Twitter
NMD PHARMA APS innovation strategy - GoodIP
We will be taking part in the ICFSR conference — NMD Pharma
NMD Pharma expands its US presence — NMD Pharma
Management team — NMD Pharma
NMD Pharma receives Orphan Drug Designation from FDA for NMD670 for the Treatment of Myasthenia Gravis | BioSpace
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Thomas Holm Pedersen (@NMDpharmaThomas) / Twitter
Management team — NMD Pharma
NMD Pharma gets green light to proceed with neuromuscular target — MedWatch
NMD Pharma will be at LSX Nordic Congress — NMD Pharma
